Zai Lab (Hong Kong) Ltd.: 药物管线_专利_临床试验_投融营收

概览

疾病领域	数量

肿瘤	1

排名前五的药物类型	数量

单克隆抗体	1

排名前五的靶点	数量

CCR8(C-C motif chemokine receptor 8)	1

关联

1

项与 Zai Lab (Hong Kong) Ltd. 相关的药物

ZL-1218

靶点

CCR8

作用机制

CCR8抑制剂 [+1]

在研机构

再鼎医药（上海）有限公司 [+2]

原研机构

再鼎医药（上海）有限公司

在研适应症

晚期恶性实体瘤 [+1]

非在研适应症-

药物最高研发状态临床1期

首次获批国家/地区-

首次获批日期-

1

项与 Zai Lab (Hong Kong) Ltd. 相关的临床试验

NCT05859464 / Recruiting临床1期

A Phase I, Open-label, Multicenter Study of ZL-1218 as a Single Agent and as Combination Therapy With Anti-PD-1 Antibody to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects With Advanced Solid Tumor Malignancies

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ZL-1218 as a single agent and as combination therapy in subjects with advanced solid tumor malignancies.

开始日期2023-07-24

申办/合作机构

Zai Lab (Hong Kong) Ltd.

[+1]

0 项与 Zai Lab (Hong Kong) Ltd. 相关的专利（医药）

登录后查看更多信息